What is U.S. Patent 8,133,893, and what medicines does it cover?
Patent 8,133,893 is a U.S. patent number, but the specific drug(s) covered depend on the patent’s title, assignee(s), and the actual claim scope. Your question asks for “pharmaceutical medicines covered,” “international patent equivalents,” and “patent expiry dates,” which require the patent’s identity details (at least the assignee and/or the patent title) or a link to the patent record.
If you paste the patent’s title/assignee (or a link), I can map the patent to the exact medicine(s) described in the claims and then list the corresponding international equivalents.
What are the “international patent equivalents” of 8,133,893?
International equivalents are typically corresponding family members filed in other jurisdictions (for example, EP, WO/PCT, CA, AU, and others), usually under the same priority application. Which countries have counterparts (and which ones are in force) depends on how the patent family was prosecuted and granted.
To list equivalents and their status, I need the patent family entry for 8,133,893 (or the priority number).
When does this patent expire (and when would generics be allowed)?
Patent expiry generally turns on:
- the filing/priority date (how long the term runs),
- whether term adjustments or extensions apply in a given country,
- whether any separate regulatory exclusivities block entry even if the patent ends.
For “generic entry,” practical timing also depends on:
- whether the generic product challenges the patent via regulatory pathways (country-specific),
- whether the patent is listed in regulatory patent registries where medicines are marketed,
- which patent(s) are the blocking ones (often multiple patents cover a single drug).
To give real expiry and generic-entry dates, I need at least the country you care about (e.g., U.S. vs. EU vs. UK vs. Canada) and the patent family details for 8,133,893.
Can generics enter before the patent expires?
Often, yes, but only if at least one of these is true:
- a court/agency decision removes the listed patent as a barrier,
- the generic is not infringing (e.g., design-around or non-covered claim elements),
- the generic is launched for an unpatented use/strength/form where permitted,
- other exclusivities or later-expiring patents do not block the specific product.
These outcomes are fact- and jurisdiction-specific and can’t be determined from the patent number alone.
What I need from you to produce the exact expiry and generic-entry dates you’re asking for
Please provide one of the following:
1) A link to the record for U.S. Patent 8,133,893 (Google Patents, USPTO, Lens.org), or
2) The patent title and assignee(s), or
3) The WO/PCT publication number or priority number.
Also tell me which market(s) you mean by “generic entry” (U.S., EU, UK, Canada, etc.).
Once you share that, I can return:
- the specific medicine(s) tied to the asserted claims,
- the international equivalents by jurisdiction,
- the calculated/observed expiry dates in each jurisdiction,
- the likely earliest generic launch window based on which patents/regulatory listings would be barriers.
Sources
No sources were used because the underlying patent record (title/assignee/claim text) for U.S. Patent 8,133,893 was not provided.